Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Study sponsor: MacroGenics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-08-11Actual
Enrollment · participants624Actual
Source updated2025-03-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.